Recently, PD-L2 expression was identified as a promising prognostic biomarker and noted to associate with low tumor-infiltrating immune cells (including CD4 + ); however, the cellular phenotype and the spatial discrimination between intra- and perifollicular localization were not investigated [36]. The gene discussed is PDCD1LG2; the disease is neoplasm.